Lycia Therapeutics, Inc.
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
Lycia Therapeutics is a biotechnology company developing therapeutics based on lysosomal targeting chimera (LYTAC) technology, which is designed to degrade disease-causing extracellular and membrane-bound proteins by directing them to the lysosome for destruction.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Venrock Healthcare Capital Partners III, L.P.10% Owner | Buy | $35.00M | 1,944,444at $18.00 | Oct 26, 2026 |
| Venrock Healthcare Capital Partners III, L.P.10% Owner | Buy | $834K | 31,067at $26.84 | Oct 27, 2026 |
| Venrock Healthcare Capital Partners III, L.P.10% Owner | Buy | $741K | 28,379at $26.11 | Oct 23, 2026 |
| Venrock Healthcare Capital Partners III, L.P.10% Owner | Buy | $631K | 24,560at $25.68 | Oct 23, 2026 |
| Venrock Healthcare Capital Partners III, L.P.10% Owner | Buy | $226K | 8,729at $25.84 | Oct 27, 2026 |
| Venrock Healthcare Capital Partners III, L.P.10% Owner | Buy | $223K | 8,261at $26.97 | Oct 26, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable LYCA activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.